Skip to main content
. 2020 Mar 16;47(10):2328–2338. doi: 10.1007/s00259-020-04760-8

Table 6.

Additive androgen deprivation therapy (ADT) in risk classes

Risk class Use of ADT (n, %) Median duration of ADT ADT medication (n, %)
Class I (low risk) 31 (27.9) 8 months (range 2–30 months)

LHRH agonist, 18 (58.1)

Antiandrogen, 10 (32.3)

Unknown, 3 (9.6)
Class II (intermediate risk) 68 (51.1) 6 months (range 1–34 months)

LHRH agonist, 40 (58.8)

Antiandrogen, 28 (41.2)
Class III (high risk) 14 (31.1) 8.5 months (range 2–21 months)

LHRH agonist, 8 (57.1)

Antiandrogen, 6 (42.9)
Class IV (very high risk) 1 (33.3) 11 months (range 11–11 months)

LHRH agonist, 1 (100.0)

Antiandrogen, 0 (0.0)

ADT, androgen deprivation therapy; LHRH, luteinizing hormone-releasing hormone